查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496232

肺病治疗市场 - 全球产业规模、份额、趋势、机会和预测，按疾病类型、治疗类型、药物类别、地区和竞争细分，2019-2029F

Lung Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Treatment Type, By Drug Class, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球肺病治疗市场估值为 784.2 亿美元，预计在预测期内将强劲成长，到 2029 年复合年增长率为 5.89%。

市场概况
预测期 2025-2029
2023 年市场规模 784.2亿美元
2029 年市场规模 1101.1亿美元
2024-2029 年复合年增长率 5.89%
成长最快的细分市场 化疗
最大的市场 北美洲

肺部疾病治疗市场涵盖广泛的药物和治疗方法，旨在解决影响肺部的各种呼吸系统疾病，包括慢性阻塞性肺病（COPD）、气喘、肺纤维化、肺癌和囊性纤维化等。作为全球发病和死亡的主要原因之一，肺部疾病对医疗保健提出了重大挑战，促使人们进行广泛的研究和开发工作以发现创新疗法。该市场的特点是治疗选择多种多样，包括支气管扩张剂、皮质类固醇、单株抗体、抗生素和标靶治疗。

支气管扩张剂，如β-激动剂和抗胆碱能药，透过放鬆气道肌肉、改善气流和减少呼吸急促来缓解症状，从而成为治疗慢性阻塞性肺病和气喘等疾病的基石。口服或吸入的皮质类固醇具有有效的抗发炎特性，对于控制气喘和慢性阻塞性肺病恶化等情况下的气道发炎至关重要。单株抗体已成为一种有前景的治疗途径，特别是在严重气喘和慢性阻塞性肺病方面，它针对与疾病发病机制有关的特定发炎途径。抗生素在治疗呼吸道感染中发挥着至关重要的作用，呼吸道感染会加剧潜在的肺部疾病并导致疾病进展。此外，标靶治疗的出现彻底改变了肺癌的治疗格局，针对致癌突变和驱动肿瘤生长的分子途径的药物，从而提供了更个性化和有效的治疗选择。

随着吸入装置和雾化器的发展提高了药物疗效、患者依从性和便利性，市场正在见证药物传输技术的重大进步。此外，由于空气污染、吸烟、人口老化和环境暴露等因素，肺部疾病盛行率不断上升，凸显了对有效治疗方法的需求不断增长。然而，市场也面临挑战，包括严格的监管要求、专利到期、仿製药竞争以及与药物开发和商业化相关的高成本。儘管有这些挑战，对疾病机制、生物标记和创新治疗方式的持续研究为肺部疾病治疗市场的持续成长和发展带来了希望，其目标是改善患者的治疗结果、生活质量，并减轻全球呼吸系统负担。

主要市场驱动因素

呼吸道疾病盛行率增加

药物开发和研究的进展

药物传输技术创新

主要市场挑战

监管障碍

专利到期和仿製药竞争

开发成本高

主要市场趋势

精准医学的进步

生物製剂和免疫疗法的采用不断增加

细分市场洞察

疾病类型见解

治疗类型见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球肺部疾病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（气喘、肺癌、慢性阻塞性肺病）
    • 依治疗类型（化疗、免疫治疗、标靶治疗、放射治疗）
    • 依药物类别（皮质类固醇、支气管扩张剂、抗菌剂、烷化剂、黏液溶解剂）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图
    • 依疾病类型
    • 按治疗类型
    • 按药物类别
    • 按地区

第 6 章：亚太地区肺病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按治疗类型
    • 按药物类别
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章：欧洲肺部疾病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按治疗类型
    • 按药物类别
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章：北美肺部疾病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按治疗类型
    • 按药物类别
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 9 章：南美肺病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按治疗类型
    • 按药物类别
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲肺部疾病治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型
    • 按治疗类型
    • 按药物类别
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 埃及

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 最近的发展
  • 产品发布（如有）
  • 併购（如有）

第 13 章：全球肺病治疗市场：SWOT 分析

第 14 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • AstraZeneca Plc.
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc.
  • Allergan Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F Hoffmann-La Roche Ltd.

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 23921

Global Lung Disease Therapeutics Market was valued at USD 78.42 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 5.89% through 2029.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 78.42 Billion
Market Size 2029USD 110.11 Billion
CAGR 2024-20295.89%
Fastest Growing SegmentChemotherapy
Largest MarketNorth America

The lung disease therapeutics market encompasses a broad spectrum of pharmaceuticals and treatments aimed at addressing various respiratory conditions affecting the lungs, including chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, lung cancer, and cystic fibrosis, among others. As one of the leading causes of morbidity and mortality worldwide, lung diseases present a significant healthcare challenge, prompting extensive research and development efforts to discover innovative therapies. The market is characterized by a diverse range of treatment options, including bronchodilators, corticosteroids, monoclonal antibodies, antibiotics, and targeted therapies.

Bronchodilators, such as beta-agonists and anticholinergics, serve to alleviate symptoms by relaxing the airway muscles, improving airflow, and reducing shortness of breath, thus representing a cornerstone in the management of conditions like COPD and asthma. Corticosteroids, administered orally or via inhalation, possess potent anti-inflammatory properties critical for controlling airway inflammation in conditions like asthma and COPD exacerbations. Monoclonal antibodies have emerged as a promising therapeutic avenue, particularly in severe asthma and COPD, targeting specific inflammatory pathways implicated in disease pathogenesis. Antibiotics play a crucial role in treating respiratory infections, which can exacerbate underlying lung conditions and contribute to disease progression. Moreover, the advent of targeted therapies has revolutionized the treatment landscape for lung cancer, with drugs targeting oncogenic mutations and molecular pathways driving tumor growth, thereby offering more personalized and effective treatment options.

The market is witnessing significant advancements in drug delivery technologies, with the development of inhalation devices and nebulizers improving drug efficacy, patient compliance, and convenience. Furthermore, the rising prevalence of lung diseases, driven by factors such as air pollution, smoking, aging populations, and environmental exposures, underscores the growing demand for effective therapeutics. However, the market also faces challenges, including stringent regulatory requirements, patent expirations, generic competition, and the high cost associated with drug development and commercialization. Despite these challenges, ongoing research into disease mechanisms, biomarkers, and innovative therapeutic modalities holds promise for the continued growth and evolution of the lung disease therapeutics market, with the goal of improving patient outcomes, quality of life, and reducing the global burden of respiratory diseases.

Key Market Drivers

Increasing Prevalence of Respiratory Diseases

The increasing prevalence of respiratory diseases is a significant driver fueling the growth of the global lung disease therapeutics market. Various factors contribute to the rising burden of respiratory conditions worldwide, including environmental pollution, tobacco smoking, aging populations, and changing lifestyles. As a result, respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis have become leading causes of morbidity and mortality, prompting a surge in demand for effective therapeutics.

COPD, characterized by chronic bronchitis and emphysema, affects millions of individuals globally and is a major contributor to the growing prevalence of respiratory diseases. Factors such as air pollution, occupational exposures to dust and chemicals, and smoking play a significant role in the development and progression of COPD. Similarly, asthma, a chronic inflammatory condition of the airways, affects over 300 million people worldwide and is influenced by genetic predisposition, environmental triggers, and allergen exposure. The increasing prevalence of asthma, particularly in urban areas with high levels of air pollution, underscores the need for improved therapeutics to manage symptoms and prevent exacerbations.

Lung cancer, a leading cause of cancer-related deaths worldwide, is closely linked to tobacco smoking, environmental carcinogens, and genetic factors. The rising incidence of lung cancer, coupled with advances in early detection and treatment, has led to a growing demand for targeted therapies and immunotherapies to improve patient outcomes. Pulmonary fibrosis, a progressive scarring of lung tissue, affects a significant number of individuals, with causes ranging from environmental exposures to genetic factors and autoimmune diseases. The increasing prevalence of pulmonary fibrosis highlights the need for innovative treatments to slow disease progression and improve quality of life.

The growing burden of respiratory diseases has led to increased healthcare spending on diagnosis, treatment, and management, driving market growth in the lung disease therapeutics sector. Pharmaceutical companies are investing in research and development to develop novel drugs, biologics, and targeted therapies to address unmet medical needs in respiratory medicine. Moreover, technological advancements in drug delivery systems, such as inhalers and nebulizers, enhance the efficacy and convenience of respiratory medications, further supporting market expansion.

Advancements in Drug Development and Research

Advancements in drug development and research play a pivotal role in boosting the global lung disease therapeutics market. Over the years, significant progress has been made in understanding the underlying mechanisms of respiratory diseases, leading to the identification of novel therapeutic targets and the development of innovative treatment modalities. One of the key drivers of advancements in drug development is the elucidation of specific molecular pathways involved in respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. Through extensive research, scientists have identified various cytokines, inflammatory mediators, and signaling pathways that contribute to the pathogenesis of these conditions. This deeper understanding has paved the way for the development of targeted therapies aimed at modulating these pathways to mitigate disease progression and improve patient outcomes.

Moreover, advancements in genomics and personalized medicine have revolutionized the treatment landscape for lung diseases. Genetic studies have uncovered key genetic variants associated with susceptibility to respiratory conditions and differential responses to treatment. This knowledge enables healthcare providers to tailor treatment regimens based on individual patient characteristics, maximizing therapeutic efficacy, and minimizing adverse effects. Precision medicine approaches are increasingly being applied in the development of lung disease therapeutics, leading to more personalized and effective treatments.

In addition to targeted therapies, advancements in drug delivery technologies have contributed to the growth of the lung disease therapeutics market. Inhalation devices, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, offer efficient and targeted delivery of medications directly to the lungs. These devices improve drug deposition in the respiratory tract, enhance patient compliance, and reduce systemic side effects compared to traditional oral medications. Furthermore, the development of long-acting and ultra-long-acting formulations extends the duration of drug action, reducing the frequency of dosing and improving patient convenience.

Technological Innovations in Drug Delivery

Technological innovations in drug delivery have significantly contributed to the growth and advancement of the global lung disease therapeutics market. These innovations have revolutionized the way respiratory medications are administered, improving efficacy, patient compliance, and overall treatment outcomes. One of the key advancements in drug delivery for lung diseases is the development of inhalation devices such as metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. These devices allow for the targeted delivery of medications directly to the lungs, bypassing the gastrointestinal tract and delivering the drug where it is needed most. MDIs, which deliver a precise dose of medication with each actuation, are commonly used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). DPIs, which deliver medications in the form of dry powder particles, offer an alternative for patients who may have difficulty coordinating their inhalation with the device. Nebulizers, which convert liquid medications into a fine mist for inhalation, are often used in the treatment of severe respiratory conditions or in patients who require higher doses of medication.

Advancements in formulation technologies have also played a significant role in improving drug delivery for lung diseases. Long-acting and ultra-long-acting formulations have been developed to extend the duration of drug action, reducing the frequency of dosing, and improving patient adherence to treatment regimens. For example, long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are commonly formulated as inhalation powders or solutions for once-daily dosing, providing sustained bronchodilation in patients with COPD. Similarly, inhaled corticosteroids (ICS) combined with LABAs or LAMAs in fixed-dose combinations offer convenient and effective treatment options for patients with asthma or COPD.

Advancements in nanotechnology and biomaterials have led to the development of novel drug delivery systems for lung diseases. Nanoparticle-based drug carriers can improve the pharmacokinetics and tissue distribution of respiratory medications, enhancing their therapeutic efficacy and reducing systemic side effects. Inhalable liposomal formulations, for example, have been investigated for the targeted delivery of chemotherapy drugs in the treatment of lung cancer, minimizing off-target toxicity and improving patient tolerance to treatment.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the lung disease therapeutics market is navigating stringent regulatory requirements imposed by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The process of obtaining regulatory approval for new drugs and therapies can be lengthy, complex, and expensive. Stringent clinical trial standards, safety assessments, and efficacy criteria must be met before a drug can be approved for market entry. Delays in the regulatory approval process can significantly impact the time-to-market for new therapies, delaying patient access to innovative treatments and hindering market growth.

Patent Expirations and Generic Competition

Patent expirations for blockbuster drugs in the lung disease therapeutics market pose a significant challenge to pharmaceutical companies, leading to increased competition from generic manufacturers. As patents expire, generic versions of branded medications enter the market, often at lower prices, leading to erosion of market share and revenue for originator companies. This loss of exclusivity can have a substantial impact on the profitability of branded drugs, prompting companies to explore strategies such as lifecycle management, product differentiation, and strategic partnerships to maintain market share and competitive advantage.

High Development Costs

The high cost of research and development (R&D) for lung disease therapeutics presents a formidable challenge for pharmaceutical companies. Developing new drugs from discovery to commercialization involves substantial investment in preclinical studies, clinical trials, regulatory submissions, and manufacturing processes. The cost of R&D is further exacerbated by the high failure rate of drug candidates in clinical trials, with many potential therapies failing to demonstrate safety or efficacy endpoints. Consequently, the high development costs associated with bringing new lung disease therapeutics to market pose a significant barrier, particularly for smaller biotechnology companies with limited financial resources.

Key Market Trends

Advancements in Precision Medicine

Advancements in precision medicine are catalyzing a transformative shift in the global lung disease therapeutics market, offering targeted and personalized treatment approaches that address the underlying molecular mechanisms of respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. Precision medicine, also known as personalized or individualized medicine, utilizes genetic information, biomarkers, and other patient-specific factors to tailor therapies to individual characteristics. In the context of lung disease therapeutics, precision medicine has led to significant advancements in the identification of specific genetic mutations and molecular pathways implicated in disease pathogenesis.

One of the most notable advancements in precision medicine is the development of targeted therapies for lung cancer. Genetic studies have identified specific driver mutations, such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and ROS1 rearrangements, which drive tumor growth in subsets of non-small cell lung cancer (NSCLC) patients. Targeted therapies such as tyrosine kinase inhibitors (TKIs) selectively inhibit these aberrant molecular pathways, leading to improved treatment outcomes and prolonged survival in patients with advanced NSCLC.

In addition to lung cancer, precision medicine approaches are also being applied to other respiratory conditions such as asthma and COPD. Genetic studies have identified genetic variants associated with increased susceptibility to asthma, as well as differential responses to asthma medications such as inhaled corticosteroids and beta-agonists. By identifying these genetic factors, clinicians can tailor treatment regimens to match the individual characteristics and needs of each patient, optimizing therapeutic efficacy and minimizing adverse effects.

Furthermore, precision medicine is driving the development of targeted biologics and immunotherapies for respiratory diseases. Monoclonal antibodies targeting specific inflammatory pathways, such as interleukin (IL)-4, IL-5, and IL-13, have shown efficacy in the treatment of severe asthma and eosinophilic COPD. Immunotherapies, including immune checkpoint inhibitors, have also shown promise in the treatment of lung cancer by harnessing the body's immune system to target cancer cells.

Rising Adoption of Biologics and Immunotherapies

The rising adoption of biologics and immunotherapies is reshaping the global lung disease therapeutics market, offering novel treatment options for respiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. Biologics, including monoclonal antibodies and recombinant proteins, target specific inflammatory pathways and molecular targets implicated in the pathogenesis of lung diseases, offering targeted and personalized treatment approaches for patients. In the treatment of severe asthma and COPD, biologics targeting key inflammatory mediators such as interleukin (IL)-4, IL-5, and IL-13 have shown promising results. These biologics, administered via subcutaneous or intravenous injection, help reduce airway inflammation, eosinophilic inflammation, and exacerbation rates in patients with severe asthma and COPD who are not adequately controlled with standard therapies. Notable examples include anti-IL-5 monoclonal antibodies such as mepolizumab, reslizumab, and benralizumab, which have demonstrated efficacy in reducing exacerbation rates and improving lung function in severe eosinophilic asthma.

In addition to asthma and COPD, biologics are also being investigated for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive fibrotic lung disease with limited treatment options. Biologics targeting key fibrotic pathways, including transforming growth factor-beta (TGF-B) and connective tissue growth factor (CTGF), have shown potential in preclinical and early clinical studies for the treatment of IPF. These biologics aim to inhibit the excessive deposition of extracellular matrix proteins and fibroblast proliferation, thereby slowing disease progression and preserving lung function in patients with IPF.

Immunotherapies, including immune checkpoint inhibitors, are revolutionizing the treatment of lung cancer by harnessing the body's immune system to target cancer cells. Immune checkpoint inhibitors such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have demonstrated significant efficacy in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with advanced or metastatic disease. These immunotherapies offer durable responses and improved survival outcomes compared to traditional chemotherapy regimens, leading to their widespread adoption as first-line and second-line treatments for NSCLC.

Segmental Insights

Disease Type Insights

Based on the disease type, asthma segment emerged as the dominant segment in the global lung disease therapeutics market in 2023. . Asthma, a widespread respiratory ailment affecting people of all ages, is a significant contributor to this dominance. Its escalating incidence, especially in urban settings characterized by elevated air pollution levels and allergen exposure, is fueling the need for efficient therapeutics to address the condition.

Asthma's prevalence globally underscores the importance of targeted treatments to manage its symptoms and prevent exacerbations. As such, pharmaceutical companies are increasingly focusing on developing innovative therapies tailored to address the specific needs of asthma patients. Additionally, advancements in medical research and technology are facilitating the discovery of novel therapeutic approaches, offering promising avenues for enhancing asthma management and improving patient outcomes. The dominance of the asthma segment in the lung disease therapeutics market reflects the substantial burden posed by this respiratory condition and the pressing demand for effective treatment options to alleviate its symptoms and enhance patients' quality of life.

Treatment Type Insights

Based on the treatment type, targeted therapy segment emerged as the dominant segment in the global lung disease therapeutics market in 2023. Targeted therapies represent a pivotal advancement in the treatment landscape by offering a personalized approach to addressing lung diseases. These therapies are designed to selectively target molecular pathways and genetic mutations involved in the pathogenesis of lung diseases, thereby enhancing treatment precision and efficacy.

In conditions like lung cancer, targeted therapies have demonstrated remarkable effectiveness in inhibiting tumor growth and improving patient outcomes. Specifically, they have shown promising results in individuals harboring specific genetic alterations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and ROS1 rearrangements. By directly targeting these aberrant molecular pathways, targeted therapies can effectively disrupt tumor progression and prolong survival in patients with these genetic mutations.

The dominance of the targeted therapy segment underscores the growing recognition of the importance of personalized medicine in lung disease treatment. As research continues to uncover novel molecular targets and genetic drivers of lung diseases, the role of targeted therapies is expected to further expand, offering new avenues for improving patient outcomes and quality of life.

Regional Insights

North America emerged as the dominant player in the global lung disease therapeutics market in 2023, holding the largest market share.This dominance can be attributed to the region's robust healthcare infrastructure and well-established pharmaceutical industry. North America boasts a plethora of leading pharmaceutical companies, esteemed research institutions, and renowned academic medical centers dedicated to advancing respiratory medicine. These entities collaborate synergistically to drive innovation, research, and development initiatives in the field of lung disease therapeutics.

The region's conducive regulatory environment, coupled with significant investments in healthcare and pharmaceutical research, further fortifies its position as a powerhouse in the global market. North America's proactive approach to healthcare innovation and its emphasis on cutting-edge therapies contribute to the continuous evolution and expansion of the lung disease therapeutics market. With a strong foundation in place, North America is poised to continue spearheading advancements in respiratory medicine, addressing unmet medical needs, and improving patient outcomes on a global scale.

Key Market Players

Novartis AG

Johnson & Johnson Services, Inc.

Amgen Inc.

AstraZeneca Plc

Boehringer Ingelheim International GmbH

Pfizer Inc.

Allergan Inc.

Bristol-Myers Squibb Company

Eli Lilly and Company

F Hoffmann-La Roche Ltd.

Report Scope:

In this report, the Global Lung Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

********Lung Disease Therapeutics Market, By Disease Type:

    Asthma Lung Cancer Chronic Obstructive Pulmonary Disease

*******Lung Disease Therapeutics Market, By Drug Class:

    Corticosteroids Bronchodilator Antimicrobial Alkylating Agents Mucolytics

*********Lung Disease Therapeutics Market, By Treatment Type:

    Chemotherapy Immunotherapy Targeted Therapy Radiation Therapy

Lung Disease Therapeutics Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Disease Therapeutics Market.

Available Customizations:

Global Lung Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Lung Disease Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease)
    • 5.2.2. By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy)
    • 5.2.3. By Drug Class (Corticosteroids, Bronchodilator, Antimicrobial, Alkylating Agents, Mucolytics)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Disease Type
    • 5.3.2. By Treatment Type
    • 5.3.3. By Drug Class
    • 5.3.4. By Region

6. Asia Pacific Lung Disease Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Drug Class
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Lung Disease Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By Drug Class
    • 6.3.2. India Lung Disease Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By Drug Class
    • 6.3.3. Australia Lung Disease Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By Drug Class
    • 6.3.4. Japan Lung Disease Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Type
        • 6.3.4.2.2. By Treatment Type
        • 6.3.4.2.3. By Drug Class
    • 6.3.5. South Korea Lung Disease Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Type
        • 6.3.5.2.2. By Treatment Type
        • 6.3.5.2.3. By Drug Class

7. Europe Lung Disease Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Drug Class
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Lung Disease Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Drug Class
    • 7.3.2. Germany Lung Disease Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Drug Class
    • 7.3.3. Spain Lung Disease Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Drug Class
    • 7.3.4. Italy Lung Disease Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Treatment Type
        • 7.3.4.2.3. By Drug Class
    • 7.3.5. United Kingdom Lung Disease Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Treatment Type
        • 7.3.5.2.3. By Drug Class

8. North America Lung Disease Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Drug Class
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Lung Disease Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Drug Class
    • 8.3.2. Mexico Lung Disease Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Drug Class
    • 8.3.3. Canada Lung Disease Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Drug Class

9. South America Lung Disease Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Drug Class
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Lung Disease Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Drug Class
    • 9.3.2. Argentina Lung Disease Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Drug Class
    • 9.3.3. Colombia Lung Disease Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Drug Class

10. Middle East and Africa Lung Disease Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Drug Class
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Lung Disease Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By Drug Class
    • 10.3.2. Saudi Arabia Lung Disease Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By Drug Class
    • 10.3.3. UAE Lung Disease Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By Drug Class
    • 10.3.4. Egypt Lung Disease Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Disease Type
        • 10.3.4.2.2. By Treatment Type
        • 10.3.4.2.3. By Drug Class

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches (If Any)
  • 12.3. Mergers & Acquisitions (If Any)

13. Global Lung Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Johnson & Johnson Services, Inc.
  • 15.3. Amgen Inc.
  • 15.4. AstraZeneca Plc.
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Pfizer Inc.
  • 15.7. Allergan Inc.
  • 15.8. Bristol-Myers Squibb Company
  • 15.9. Eli Lilly and Company
  • 15.10. F Hoffmann-La Roche Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer